TrialFind
Saved trials

Filters

Status

Phase

Age group

TrialFind

Data sourced from ClinicalTrials.gov. Always consult a healthcare provider before enrolling.

PrivacyData sourcesRegulatory infoContact
CompletedPhase 1

A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine)

This study will evaluate four different modified release formulation to estimate the amount of dimebon available to the body relative to the current dimebon formulation that is given three times a day. The results of this study will help in

New Haven, Connecticut, United StatesView details
CompletedPhase 4

A 12 Week, Multicenter, Open Label Evaluation of Caregiver Preference, Safety and Tolerability of Exelon® Patch (Rivastigmine Transdermal) in Patients With Alzheimer's Disease

This study is designed to evaluate caregiver preference for Exelon® patch (target patch size 10 cm²) treatment in patients with Alzheimer's disease (MMSE 10-26) who were under cholinesterase inhibitor treatment and experienced adverse event

Ashkelon, Israel+4 moreView details
CompletedPhase 1

Brain Uptake of GSK1034702: a Positron Emission Tomography (PET) Scan Study

GSK1034702 is being developed for improving cognitive impairment in diseases such as Alzheimer's disease and schizophrenia. This study will be done in healthy men to investigate how much of the study drug gets into the brain.

London, United Kingdom+1 moreView details
Recruiting

Feasibility and Interest of the 3D Ephemeris for Temporal Orientation in Alzheimer's: Pilot Study

In geriatric care, occupational therapists use validated tools to assess abilities and performance, identifying deficiencies and proposing rehabilitation programs. Temporal orientation disorders are common, with studies showing that individ

Champcueil, FranceView details
CompletedN/A

Effect of Scene-Based Training on Cognitive Function in Patients With Alzheimer's Disease

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, including impairments in orientation, memory, and daily functioning. Orientation dysfunction, involving difficulties in recognizing tim

Hangzhou, Zhejiang, ChinaView details
RecruitingPhase 3

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)

The purpose of this study is to evaluate KarXT + KarX-EC as a treatment for psychosis associated with Alzheimer's disease.

Gilbert, Arizona, United States+19 moreView details
RecruitingPhase 1

UAB Alzheimer's Disease Center Core Cohort - Tau Imaging Substudy

The primary objective of this study is to measure the concentration and the regional brain distribution of pathologic tau deposition using the PET tracer AV-1451 in participants in the UAB-ADC cohort. The amount and distribution of AV-1451

Birmingham, Alabama, United StatesView details
CompletedPhase 2 / Phase 3

A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)

The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.

Phoenix, Arizona, United States+39 moreView details
CompletedPhase 3

Agitation in Alzheimer's Disease

Agitation affects 70 to 90 percent of patients with AD. Signs of agitation include verbal and physical aggressiveness, irritability, wandering, and restlessness.

Los Angeles, California, United States+15 moreView details
CompletedPhase 2

Multiple IV Dose Study Of PF-04360365 In Patients With Mild To Moderate Alzheimer's Disease

Purpose of the study is to determine whether multiple dose administration of PF-04360365 is safe and well tolerated in patient with mild to moderate Alzheimer's disease.

Peoria, Arizona, United States+41 moreView details
CompletedPhase 2

Deferiprone to Delay Dementia (The 3D Study)

This study is a phase 2, randomised, placebo-controlled, multicentre study to investigate the safety and efficacy of Deferiprone in participants with Prodromal Alzheimer's Disease (pAD) and Mild Alzheimer's Disease (mAD). In this phase 2 st

Macquarie Park, New South Wales, Australia+7 moreView details
RecruitingN/A

Gamma Light and Sound Stimulation to Prevent Dementia in Cognitively Normal People At Risk for Alzheimer's Disease

Alzheimer's disease (AD) is characterized by significant memory loss, toxic protein deposits (amyloid and tau) in the brain, and changes in the gamma frequency band on EEG. Gamma waves are important for memory, and in patients with AD, ther

Boston, Massachusetts, United States+1 moreView details
CompletedN/A

Medium Chain Triglycerides and Brain Metabolism in Alzheimer's Disease

Evaluate and compare the changes in brain ketone and glucose uptake after taking two different MCT oil emulsions (60-40 oil or C8 oil) for one month, in a group of people with Alzheimer's disease and a control group.

Sherbrooke, Quebec, CanadaView details
CompletedPhase 3

Ginkgo Biloba Prevention Trial in Older Individuals

This study will determine the effect of 240mg/day Ginkgo biloba in decreasing the incidence of dementia and specifically Alzheimer's disease (AD), slowing cognitive decline and functional disability, reducing incidence of cardiovascular dis

Sacramento, California, United States+4 moreView details
Not yet recruitingPhase 1

Effect of Food and Age on the Pharmacokinetics of LY03017

This study consists of 2 parts. Part A is a randomized, open-label, 2-period, crossover study to evaluate the food effect of LY03017 in healthy adults.

Shanghai, ChinaView details
Completed

A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits

REINVENT is a non-interventional, multi-center, research network-based cross-over study evaluating the potential utility of a telehealth platform in improving the efficiency of clinical trials. The study aims to enroll 30 subjects from prim

Gilbert, Arizona, United StatesView details
CompletedPhase 2

Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI)

This research is being done to find out if daily use of the drug levetiracetam can improve memory function in individuals with memory problems like those associated with Mild Cognitive Impairment (MCI) and Alzheimer's disease (AD).

Baltimore, Maryland, United StatesView details
Active, not recruitingN/A

Does EVOO Induce Gene and Metabolic Changes in Healthy Subjects

Investigators' recent findings from the pilot clinical trial in MCI individuals demonstrated EVOO improved vascular function and memory. Yet, up to date, whether EVOO protects against AD in individuals with a family history of AD is unknown

Augusta, Georgia, United StatesView details
RecruitingPhase 2

A Study of NTRX-07 in Participants With Alzheimer's Disease

1. Study Overview NeuroTherapia Inc.

Brno, Czechia+5 moreView details
Recruiting

Cognitive Leisure and Preclinical Alzheimer's Disease: Exploring Neural Mechanisms

The goal of this clinical trial is aims to: 1. Translate and culturally adapt the Cognitive Leisure Activity Scale (CLAS) into Chinese and Conduct reliability and validity tests for the Chinese version of CLAS.

Fuzhou, Fujian, ChinaView details
Load more trials